title: Hepatic glucose disposition during concomitant portal glucose and amino acid infusions in the dog.
abstract: The effect of concomitant intraportal infusion of glucose and gluconeogenic amino acids (AA) on net hepatic glucose uptake (NHGU) and glycogen synthesis was examined in 42-h-fasted dogs. After a basal period, there was a 240-min experimental period during which somatostatin was infused continuously into a peripheral vein and insulin and glucagon (at 3-fold basal and basal rates, respectively) and glucose (18.3 mumol.kg-1.min-1) were infused intraportally. One group (PoAA, n = 7) received an AA mixture intraportally at 7.6 mumol.kg-1.min-1, whereas the other group (NoAA, n = 6) did not receive AA. Arterial blood glucose concentrations and hepatic glucose loads were the same in the two groups. NHGU averaged 4.8 +/- 2.0 (PoAA) and 9.4 +/- 2.0 (NoAA) mumol.kg-1.min-1 (P < 0.05), and tracer-determined hepatic glucose uptake was 4.6 +/- 1.6 (PoAA) and 10.0 +/- 1.7 (NoAA) mumol.kg-1.min-1 (P < 0.05). AA data for PoAA and NoAA, respectively, were as follows: arterial blood concentrations, 1,578 +/- 133 vs. 1,147 +/- 86 microM (P < 0.01); hepatic loads, 56 +/- 3 vs. 32 +/- 4 mumol.kg-1.min-1 (P < 0.01); and net hepatic uptakes, 14.1 +/- 1.4 vs. 5.6 +/- 0.4 mumol.kg-1.min-1 (P < 0.01). The rate of net hepatic glycogen synthesis was 7.5 +/- 1.9 (PoAA) vs. 10.7 +/- 2.3 (NoAA) mumol.kg-1.min-1 (P = 0.1). In a net sense, intraportal gluconeogenic amino acid delivery directed glucose carbon away from the liver. Despite this, net hepatic carbon uptake was equivalent in the presence and absence of amino acid infusion.
authors.affiliation: Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee 37232-0615, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Moore
authors.forename: P J
authors.initials: PJ
authors.lastname: Flakoll
authors.forename: P S
authors.initials: PS
authors.lastname: Hsieh
authors.forename: M J
authors.initials: MJ
authors.lastname: Pagliassotti
authors.forename: D W
authors.initials: DW
authors.lastname: Neal
authors.forename: M T
authors.initials: MT
authors.lastname: Monohan
authors.forename: C
authors.initials: C
authors.lastname: Venable
authors.forename: A D
authors.initials: AD
authors.lastname: Cherrington
mesh_terms: D000596:Amino Acids / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004285:Dogs; D005260:Female; D005934:Glucagon / Q000097:blood; D005943:Gluconeogenesis / Q000502:physiology; D005947:Glucose / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006003:Glycogen / Q000096:biosynthesis; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D007773:Lactates / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008102:Liver Circulation / Q000502:physiology; D008297:Male; D009994:Osmolar Concentration; D011169:Portal Vein
chemical_list: D000596:Amino Acids; D001786:Blood Glucose; D007328:Insulin; D007773:Lactates; D006003:Glycogen; D005934:Glucagon; D005947:Glucose